MetaVia (NASDAQ:MTVA) Earns Buy Rating from HC Wainwright

MetaVia (NASDAQ:MTVAGet Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $12.00 price objective on the stock.

MetaVia Price Performance

MetaVia stock opened at $0.81 on Wednesday. MetaVia has a 12 month low of $0.81 and a 12 month high of $5.30. The stock has a fifty day simple moving average of $1.53.

MetaVia Company Profile

(Get Free Report)

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.

Recommended Stories

Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.